TET2 might be a therapeutic target for atherosclerosis

被引：1
|
作者：
Wang, Yu [1 ]
Zhao, Danyang [2 ]
Lu, Ping [1 ]
Sheng, Jing [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Geriatr, Shanghai 200011, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Plast & Reconstruct Surg, Shanghai 200011, Peoples R China
来源：
INTERNATIONAL JOURNAL OF CARDIOLOGY | 2016年 / 203卷
关键词：
DNA METHYLATION;
D O I：
10.1016/j.ijcard.2015.10.052
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：396 / 397
页数：2
相关论文
共 50 条
  • [1] TET2: A Novel Epigenetic Regulator and Potential Intervention Target for Atherosclerosis
    Liu, Yami
    Peng, Wen
    Qu, Kai
    Lin, Xiaolong
    Zeng, Zhaolin
    Chen, Jiaojiao
    Wei, Dangheng
    Wang, Zuo
    DNA AND CELL BIOLOGY, 2018, 37 (06) : 517 - 523
  • [2] TET2 mutations in Diffuse Large B-Cell Lymphoma: The Role of TET2 in the Regulation of Methylation Patterns at TET2 Target Genes
    Asmar, Fazila
    Christensen, Jesper
    Johansen, Jens V.
    Blabjerg, Anders
    Pedersen, Anja
    Hother, Christoffer
    Ralfkiaer, Ulrik
    Helin, Kristian
    Gronbaek, Kirsten
    BLOOD, 2011, 118 (21) : 598 - 599
  • [3] TET2 as a tumor suppressor and therapeutic target in T-cell acute lymphoblastic leukemia
    Bensberg, Maike
    Rundquist, Olof
    Selimovic, Aida
    Lagerwall, Cathrine
    Benson, Mikael
    Gustafsson, Mika
    Vogt, Hartmut
    Lentini, Antonio
    Nestor, Colm E.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2021, 118 (34)
  • [4] TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia
    Guan, Yihong
    Tiwari, Anand D.
    Phillips, James G.
    Hasipek, Metis
    Grabowski, Dale
    Kerr, Cassandra M.
    Adema, Vera
    Nagata, Yasunobu
    Visconte, Valeria
    Radivoyevitch, Tomas
    Lindner, Daniel
    Meggendorfer, Manja
    Abazeed, Mohamed
    Sekeres, Mikkael A.
    Haferlach, Torsten
    Maciejewski, Jaroslaw P.
    Jha, Babal K.
    BLOOD, 2019, 134
  • [5] Characterization of MDS Harboring TET2 Mutations and/or TET2 Deletions
    Haferlach, Claudia
    Stengel, Anna
    Meggendorfer, Manja
    Kern, Wolfgang
    Haferlach, Torsten
    BLOOD, 2016, 128 (22)
  • [6] TET2: the terminator
    Bird, Lucy
    NATURE REVIEWS IMMUNOLOGY, 2015, 15 (10) : 598 - 598
  • [7] TET2: the terminator
    Lucy Bird
    Nature Reviews Immunology, 2015, 15 : 598 - 598
  • [8] Inhibition of myeloperoxidase might be a novel therapeutic target in the treatment of atherosclerosis
    Wang, Wei
    Ren, Dong
    Wang, Chunsong
    Gong, Ying
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 256 : 33 - 33
  • [9] Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice
    Fuster, Jose J.
    MacLauchlan, Susan
    Zuriaga, Maria A.
    Polackal, Maya N.
    Ostriker, Allison C.
    Chakraborty, Raja
    Wu, Chia-Ling
    Sano, Soichi
    Muralidharan, Sujatha
    Rius, Cristina
    Vuong, Jacqueline
    Jacob, Sophia
    Muralidhar, Varsha
    Robertson, Avril A. B.
    Cooper, Matthew A.
    Andres, Vicente
    Hirschi, Karen K.
    Martin, Kathleen A.
    Walsh, Kenneth
    SCIENCE, 2017, 355 (6327) : 842 - 847
  • [10] FISHing for TET2: Utility of FISH for TET2 deletions detection in clinical samples
    Soriano Pignataro, Daniela
    Abdel-Wahab, Omar
    LEUKEMIA RESEARCH, 2012, 36 (01) : 25 - 26
12345